Particle.news
Download on the App Store

Pacira Presses Shareholders to Back Its Board in Active Proxy Fight

The company says recent profitability, a 2025 EXPAREL settlement that preserves commercial exclusivity, and planned R&D readouts justify keeping current directors.

Overview

  • Pacira is asking investors to vote FOR its three nominees on the company’s BLUE proxy card and to disregard the white card sent by activist investor DOMA in the run-up to the June 9, 2026 annual meeting.
  • The company points to 2025 results as proof of momentum, reporting record revenue of $726.4 million, GAAP net income of $7.0 million and non‑GAAP net income of $122.3 million together with record gross margins.
  • Pacira credits its multi‑year '5x30' strategy for renewed performance and says the stock has risen more than 31% since the plan launched.
  • Pacira says a 2025 EXPAREL settlement gives it full exclusivity through 2030 with a gradual, capped transition through 2039 and that the deal protects near‑term commercial revenue.
  • The board says it has extensively engaged holders representing 97.4% of shares, met with DOMA 17 times, interviewed two DOMA nominees, found DOMA’s candidates not value‑add, and flagged three expected R&D data readouts by year‑end as further potential catalysts.